Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 224

1.

Risk of all-cause mortality in HIV infected patients is associated with clinical, immunologic predictors and the CCR5 Δ32 deletion.

Parczewski M, Bander D, Leszczyszyn-Pynka M, Urbanska A, Kaczmarczyk M, Ciechanowicz A, Boron-Kaczmarska A.

PLoS One. 2011;6(7):e22215. doi: 10.1371/journal.pone.0022215. Epub 2011 Jul 18.

2.
3.

Is long-term virological response related to CCR5 Delta32 deletion in HIV-1-infected patients started on highly active antiretroviral therapy?

Laurichesse JJ, Taieb A, Capoulade-Metay C, Katlama C, Villes V, Drobacheff-Thiebaud MC, Raffi F, Chêne G, Theodorou I, Leport C; ANRS C08 Aproco-Copilote Study Group.

HIV Med. 2010 Apr;11(4):239-44. doi: 10.1111/j.1468-1293.2009.00769.x. Epub 2009 Dec 28.

4.

Improved virological response to highly active antiretroviral therapy in HIV-1-infected patients carrying the CCR5 Delta32 deletion.

Laurichesse JJ, Persoz A, Theodorou I, Rouzioux C, Delfraissy JF, Meyer L.

HIV Med. 2007 May;8(4):213-9.

5.

MT-2 tropism and CCR-5 genotype strongly influence disease progression in HIV-1-infected individuals.

Bratt G, Leandersson AC, Albert J, Sandström E, Wahren B.

AIDS. 1998 May 7;12(7):729-36.

PMID:
9619804
6.

Effects of CCR5-delta32 and CCR2-64I alleles on disease progression of perinatally HIV-1-infected children: an international meta-analysis.

Ioannidis JP, Contopoulos-Ioannidis DG, Rosenberg PS, Goedert JJ, De Rossi A, Espanol T, Frenkel L, Mayaux MJ, Newell ML, Pahwa SG, Rousseau C, Scarlatti G, Sei S, Sen L, O'Brien TR; HIV Host Genetics International Meta-Analysis Group.

AIDS. 2003 Jul 25;17(11):1631-8.

PMID:
12853745
7.

IL28B CC genotype is associated with higher all-cause mortality in antiretroviral-treated HIV-infected patients.

Parczewski M, Bander D, Leszczyszyn-Pynka M, Urbańska A, Socha Ł, Boroń-Kaczmarska A.

AIDS Res Hum Retroviruses. 2012 Dec;28(12):1640-6. doi: 10.1089/AID.2011.0354. Epub 2012 Jun 4.

PMID:
22545770
8.

Predictors of mortality among HIV-infected women in Kigali, Rwanda.

Lindan CP, Allen S, Serufilira A, Lifson AR, Van de Perre P, Chen-Rundle A, Batungwanayo J, Nsengumuremyi F, Bogaerts J, Hulley S.

Ann Intern Med. 1992 Feb 15;116(4):320-8.

PMID:
1733389
9.

Homozygous and heterozygous CCR5-Delta32 genotypes are associated with resistance to HIV infection.

Marmor M, Sheppard HW, Donnell D, Bozeman S, Celum C, Buchbinder S, Koblin B, Seage GR 3rd; HIV Network for Prevention Trials Vaccine Preparedness Protocol Team.

J Acquir Immune Defic Syndr. 2001 Aug 15;27(5):472-81.

PMID:
11511825
10.

Reduced renal function is associated with progression to AIDS but not with overall mortality in HIV-infected Kenyan adults not initially requiring combination antiretroviral therapy.

Gupta SK, Ong'or WO, Shen C, Musick B, Goldman M, Wools-Kaloustian K.

J Int AIDS Soc. 2011 Jun 11;14:31. doi: 10.1186/1758-2652-14-31.

11.

Relationship between CCR5(WT/Δ32) heterozygosity and HIV-1 reservoir size in adolescents and young adults with perinatally acquired HIV-1 infection.

Martínez-Bonet M, González-Serna A, Clemente MI, Morón-López S, Díaz L, Navarro M, Puertas MC, Leal M, Ruiz-Mateos E, Martinez-Picado J, Muñoz-Fernández MA.

Clin Microbiol Infect. 2017 May;23(5):318-324. doi: 10.1016/j.cmi.2016.12.020. Epub 2016 Dec 29.

12.

Frequency of CCR5-Delta32 deletion in human immunodeficiency virus type 1 (HIV-1) in healthy blood donors, HIV-1-exposed seronegative and HIV-1-seropositive individuals of southern Brazilian population.

Reiche EM, Ehara Watanabe MA, Bonametti AM, Morimoto HK, Akira Morimoto A, Wiechmann SL, Matsuo T, Carvalho De Oliveira J, Vissoci Reiche F.

Int J Mol Med. 2008 Nov;22(5):669-75.

PMID:
18949389
13.

HIV-1-infected long-term slow progressors heterozygous for delta32-CCR5 show significantly lower plasma viral load than wild-type slow progressors.

Walli R, Reinhart B, Luckow B, Lederer E, Loch O, Malo A, Wank R, Schlöndorff D, Goebel FD.

J Acquir Immune Defic Syndr Hum Retrovirol. 1998 Jul 1;18(3):229-33.

PMID:
9665499
14.

[Mortality of HIV infected clients treated with methadone maintenance treatment in Yili Kazakh autonomous prefecture].

Liu EW, Wang SJ, Liu Y, Liu W, Chen ZS, Li XY, A LY, Wu ZY.

Zhonghua Yu Fang Yi Xue Za Zhi. 2011 Nov;45(11):979-84. Chinese.

PMID:
22336271
15.

Protective effect of CCR5-Δ32 against HIV infection by the heterosexual mode of transmission in a Polish population.

Zwolińska K, Knysz B, Rybka K, Pazgan-Simon M, Gąsiorowski J, Sobczyński M, Gładysz A, Piasecki E.

AIDS Res Hum Retroviruses. 2013 Jan;29(1):54-60. doi: 10.1089/AID.2011.0362. Epub 2012 Oct 9.

PMID:
22957692
16.

Clinical predictors of immune reconstitution following combination antiretroviral therapy in patients from the Australian HIV Observational Database.

Rajasuriar R, Gouillou M, Spelman T, Read T, Hoy J, Law M, Cameron PU, Petoumenos K, Lewin SR.

PLoS One. 2011;6(6):e20713. doi: 10.1371/journal.pone.0020713. Epub 2011 Jun 2.

17.

Incidence, timing, and determinants of bacterial pneumonia among HIV-infected patients: data from the ICONA Foundation Cohort.

Mussini C, Galli L, Lepri AC, De Luca A, Antinori A, Libertone R, Angarano G, Bonfanti P, Castagna A, DʼArminio Monforte A; ICONA Foundation Study Group.

J Acquir Immune Defic Syndr. 2013 Jul 1;63(3):339-45. doi: 10.1097/QAI.0b013e318295ab85.

PMID:
23591636
18.

Determinants of clinical progression in antiretroviral-naive HIV-infected patients starting highly active antiretroviral therapy. Aquitaine Cohort, France, 1996-2002.

Bonnet F, Thiébaut R, Chêne G, Neau D, Pellegrin JL, Mercié P, Beylot J, Dabis F, Salamon R, Morlat P; Groupe d'Epidemiologie Clinique du SIDA en Aquitaine (GECSA).

HIV Med. 2005 May;6(3):198-205.

19.

Interruption of combination antiretroviral therapy and risk of clinical disease progression to AIDS or death.

Holkmann Olsen C, Mocroft A, Kirk O, Vella S, Blaxhult A, Clumeck N, Fisher M, Katlama C, Phillips AN, Lundgren JD; EuroSIDA study group.

HIV Med. 2007 Mar;8(2):96-104.

20.

Association between CCR5 genotype and the clinical course of HIV-1 infection.

de Roda Husman AM, Koot M, Cornelissen M, Keet IP, Brouwer M, Broersen SM, Bakker M, Roos MT, Prins M, de Wolf F, Coutinho RA, Miedema F, Goudsmit J, Schuitemaker H.

Ann Intern Med. 1997 Nov 15;127(10):882-90.

PMID:
9382366

Supplemental Content

Support Center